Evidence map›Paper›PMID 31192483›Full record

ReviewMedicinal research reviews2020

Inducible nitric oxide synthase: Regulation, structure, and inhibition.

Maris A Cinelli, Ha T Do, Galen P Miley, Richard B Silverman

Open access · greenAbstract readReview
In one paragraph

Review in Medicinal research reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 388 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
388citing papers in PubMed, 4 pooled it
33.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

388 citing papers in PubMed, 4 syntheses or guidelines pooled it, 820 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Epithelial Inflammatory iNOS-Nitrate Axis EnhancesInternational journal of molecular sciences · 2026
    Article
  10. Article
  11. Article
  12. [Isolation, purification and immunomodulatory activity of polysaccharide fromNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  13. Article
  14. Sustainable Valorization ofMolecules (Basel, Switzerland) · 2026
    Article
  15. Review
  16. Article
  17. LC-MS/MS Chemical Profiling and HPLC/PDA Quantification ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  18. Review
  19. Article
  20. Article

328 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Maris A CinelliDepartment of Chemistry, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois.ORCID 0000-0002-5887-7038
Ha T DoDepartment of Chemistry, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois.
Galen P MileyDepartment of Chemistry, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois.
Richard B SilvermanDepartment of Chemistry, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois.ORCID 0000-0001-9034-1084
Northwestern University · US

Funding

Selective inhibition of nitric oxide synthase for multiple indicationsR01GM049725 · NIGMS · NORTHWESTERN UNIVERSITY · PI SILVERMAN, RICHARD B · 1994 to 2018
$6.0M
Chemistry of Life Processes Predoctoral Training ProgramT32GM105538 · NIGMS · NORTHWESTERN UNIVERSITY · PI KELLEHER, NEIL L · 2013 to 2022
$2.7M
Design, Synthesis, and Biology of Inhibitors of Neuronal Nitric Oxide SynthaseF32GM109667 · NIGMS · NORTHWESTERN UNIVERSITY · PI CINELLI, MARIS A · 2014 to 2015
$109k
NIGMS NIH HHS F32 GM109667NIGMS NIH HHS R01 GM049725NIGMS NIH HHS T32 GM105538
6 · The paper itself

Abstract

A considerable number of human diseases have an inflammatory component, and a key mediator of immune activation and inflammation is inducible nitric oxide synthase (iNOS), which produces nitric oxide (NO) from l-arginine. Overexpressed or dysregulated iNOS has been implicated in numerous pathologies including sepsis, cancer, neurodegeneration, and various types of pain. Extensive knowledge has been accumulated about the roles iNOS plays in different tissues and organs. Additionally, X-ray crystal and cryogenic electron microscopy structures have shed new insights on the structure and regulation of this enzyme. Many potent iNOS inhibitors with high selectivity over related NOS isoforms, neuronal NOS, and endothelial NOS, have been discovered, and these drugs have shown promise in animal models of endotoxemia, inflammatory and neuropathic pain, arthritis, and other disorders. A major issue in iNOS inhibitor development is that promising results in animal studies have not translated to humans; there are no iNOS inhibitors approved for human use. In addition to assay limitations, both the dual modalities of iNOS and NO in disease states (ie, protective vs harmful effects) and the different roles and localizations of NOS isoforms create challenges for therapeutic intervention. This review summarizes the structure, function, and regulation of iNOS, with focus on the development of iNOS inhibitors (historical and recent). A better understanding of iNOS' complex functions is necessary before specific drug candidates can be identified for classical indications such as sepsis, heart failure, and pain; however, newer promising indications for iNOS inhibition, such as depression, neurodegenerative disorders, and epilepsy, have been discovered.

Indexed as

AnimalsDiseaseEnzyme InhibitorsHumansModels, BiologicalNitric OxideNitric Oxide Synthase Type IISignal TransductionEnzyme InhibitorsNitric OxideNitric Oxide Synthase Type IIanimal modelscancerenzyme inhibitionimmune regulationimmune system activationinducible nitric oxide synthaseinflammationneurodegenerationnitrergic signalingnitric oxidepainreactive oxygen speciessepsis

Identifiers

PMID31192483
PMCPMC6908786
OpenAlexW2949112913

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.